T1	Treatment 0 55	Rituximab plus concurrent infusional EPOCH chemotherapy
T2	Treatment 466 732	rituximab (375 mg/m(2)) given either concurrently before each infusional etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone (EPOCH) chemotherapy cycle or sequentially (weekly for 6 weeks) after completion of all chemotherapy in HIV-associated NHL.
T3	Treatment 733 738	EPOCH
T4	Treatment 786 846	etoposide, doxorubicin, and vincristine plus oral prednisone
T5	Treatment 877 893	cyclophosphamide
T6	Treatment 1408 1450	concurrent rituximab plus infusional EPOCH
